Mechanistically, Mt2 regulates cerebrovascular compliance via modulating the release of migraine‐associated mediators (CGRP, IL‐6, TNF‐α), thereby establishing an interface between vascular tone dysregulation and migraine‐like pain thresholds. Here, IL6 is linked to migraine disorder.